Agios Reports Q3 2025 Earnings with Revenue Growth and Regulatory Updates
Agios (AGIO) reported Q3 2025 earnings with net revenue of $12.9 million, showing 44% year-over-year growth. The company also provided updates on the FDA review timeline for PYRUKYND and global regulatory approvals. Research and development expenses rose due to clinical trial costs.
Tickers: $AGIO
Topics: Clinical Trials FDA Approval PYRUKYND Regulatory Progress Revenue Growth